Fill in this information to identify the case:

Debtor Red Queen Therapeutics, Inc.

United States Bankruptcy Court for the: _____ District of Delaware (State)

Case number 25-12204

Modified Official Form 410

Proof of Claim

04/25

Read the instructions before filling out this form. This form is for making a claim for payment in a bankruptcy case. Do not use this form to make a request for payment of an administrative expense. Make such a request according to 11 U.S.C. § 503.

Filers must leave out or redact information that is entitled to privacy on this form or on any attached documents. Attach redacted copies or any documents that support the claim, such as promissory notes, purchase orders, invoices, itemized statements of running accounts, contracts, judgments, mortgages, and security agreements. **Do not send original documents;** they may be destroyed after scanning. If the documents are not available, explain in an attachment.

A person who files a fraudulent claim could be fined up to $500,000, imprisoned for up to 5 years, or both. 18 U.S.C. §§ 152, 157, and 3571.

Fill in all the information about the claim as of the date the case was filed. That date is on the notice of bankruptcy (Form 309) **that you received.**

Part 1: Identify the Claim

1. **Who is the current creditor?**

Bachem Americas, Inc.

Name of the current creditor (the person or entity to be paid for this claim)

Other names the creditor used with the debtor Red Queen Therapeutics

2. **Has this claim been acquired from someone else?**

☑ No

☐ Yes. From whom? _____

3. **Where should notices and payments to the creditor be sent?**

Federal Rule of Bankruptcy Procedure (FRBP) 2002(g)

Where should notices to the creditor be sent?	**Where should payments to the creditor be sent?** (if different)
See summary page	
Contact phone _____	Contact phone _____
Contact email steve.brenner@bachem.com	Contact email _____

Uniform claim identifier (if you use one):

_ _

4. **Does this claim amend one already filed?**

☑ No

☐ Yes. Claim number on court claims registry (if known) _____ Filed on _____ MM / DD / YYYY

5. **Do you know if anyone else has filed a proof of claim for this claim?**

☑ No

☐ Yes. Who made the earlier filing? _____

25122042607070000000000001

Part 2: Give Information About the Claim as of the Date the Case Was Filed

6. **Do you have any number you use to identify the debtor?**

☐ No

☑ Yes. Last 4 digits of the debtor's account or any number you use to identify the debtor: 9536

7. **How much is the claim?** $ 53,072.38 . **Does this amount include interest or other charges?**

☑ No

☐ Yes. Attach statement itemizing interest, fees, expenses, or other charges required by Bankruptcy Rule 3001(c)(2)(A).

8. **What is the basis of the claim?**

Examples: Goods sold, money loaned, lease, services performed, personal injury or wrongful death, or credit card.

Attach redacted copies of any documents supporting the claim required by Bankruptcy Rule 3001(c).

Limit disclosing information that is entitled to privacy, such as health care information.

Costs incurred for services

9. **Is all or part of the claim secured?**

☑ No

☐ Yes. The claim is secured by a lien on property.

Nature or property:

☐ Real estate: If the claim is secured by the debtor's principle residence, file a *Mortgage Proof of Claim Attachment* (Official Form 410-A) with this *Proof of Claim*.

☐ Motor vehicle

☐ Other. Describe: _____

Basis for perfection: _____

Attach redacted copies of documents, if any, that show evidence of perfection of a security interest (for example, a mortgage, lien, certificate of title, financing statement, or other document that shows the lien has been filed or recorded.)

Value of property: $_____

Amount of the claim that is secured: $_____

Amount of the claim that is unsecured: $_____ (The sum of the secured and unsecured amount should match the amount in line 7.)

Amount necessary to cure any default as of the date of the petition: $_____

Annual Interest Rate (when case was filed)_____%

☐ Fixed

☐ Variable

10. **Is this claim based on a lease?**

☑ No

☐ Yes. **Amount necessary to cure any default as of the date of the petition.** $_____

11. **Is this claim subject to a right of setoff?**

☑ No

☐ Yes. Identify the property: _____

25122042607070000000000001

12. **Is all or part of the claim entitled to priority under 11 U.S.C. § 507(a)?**

A claim may be partly priority and partly nonpriority. For example, in some categories, the law limits the amount entitled to priority.

☑ No

☐ Yes. *Check all that apply:*

	Amount entitled to priority
☐ Domestic support obligations (including alimony and child support) under 11 U.S.C. § 507(a)(1)(A) or (a)(1)(B).	$_____
☐ Up to $3,800* of deposits toward purchase, lease, or rental of property or services for personal, family, or household use. 11 U.S.C. § 507(a)(7).	$_____
☐ Wages, salaries, or commissions (up to $17,150*) earned within 180 days before the bankruptcy petition is filed or the debtor's business ends, whichever is earlier. 11 U.S.C. § 507(a)(4).	$_____
☐ Taxes or penalties owed to governmental units. 11 U.S.C. § 507(a)(8).	$_____
☐ Contributions to an employee benefit plan. 11 U.S.C. § 507(a)(5).	$_____
☐ Other. Specify subsection of 11 U.S.C. § 507(a)(__) that applies.	$_____

* Amounts are subject to adjustment on 4/01/28 and every 3 years after that for cases begun on or after the date of adjustment.

13. **Is all or part of the claim entitled to administrative priority pursuant to 11 U.S.C. § 503(b)(9)?**

☑ No

☐ Yes. Indicate the amount of your claim arising from the value of any goods received by the debtor within 20 days before the date of commencement of the above case, in which the goods have been sold to the Debtor in the ordinary course of such Debtor's business. Attach documentation supporting such claim.

$_____

Part 3: Sign Below

The person completing this proof of claim must sign and date it. FRBP 9011(b).

If you file this claim electronically, FRBP 5005(a)(3) authorizes courts to establish local rules specifying what a signature is.

A person who files a fraudulent claim could be fined up to $500,000, imprisoned for up to 5 years, or both. 18 U.S.C. §§ 152, 157, and 3571.

Check the appropriate box:

☑ I am the creditor.

☐ I am the creditor's attorney or authorized agent.

☐ I am the trustee, or the debtor, or their authorized agent. Bankruptcy Rule 3004.

☐ I am a guarantor, surety, endorser, or other codebtor. Bankruptcy Rule 3005.

I understand that an authorized signature on this *Proof of Claim* serves as an acknowledgement that when calculating the amount of the claim, the creditor gave the debtor credit for any payments received toward the debt.

I have examined the information in this *Proof of Claim* and have reasonable belief that the information is true and correct.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on date 07/07/2026
MM / DD / YYYY

/s/Steve Brenner
Signature

Print the name of the person who is completing and signing this claim:

Name: Steve Brenner
First name Middle name Last name

Title: Legal Counsel

Company: Bachem Americas, Inc.
Identify the corporate servicer as the company if the authorized agent is a servicer.

Address

Contact phone _____ Email _____

25122042607070000000000001

Verita (KCC) ePOC Electronic Claim Filing Summary

For phone assistance: Domestic 866-927-7091 | International 310-751-2657

Debtor:
25-12204 - Red Queen Therapeutics, Inc.
District:
District of Delaware

Creditor:
Bachem Americas, Inc.
Legal Department
3170 Kashiwa Street

Torrance, California, 90505
United States
Phone:
Phone 2:
Fax:
Email:
steve.brenner@bachem.com

Has Supporting Documentation:
Yes, supporting documentation successfully uploaded
Related Document Statement:

Has Related Claim:
No
Related Claim Filed By:

Filing Party:
Creditor

Other Names Used with Debtor:
Red Queen Therapeutics

Amends Claim:
No
Acquired Claim:
No

Basis of Claim:
Costs incurred for services

Last 4 Digits:
Yes - 9536

Uniform Claim Identifier:

Total Amount of Claim:
53,072.38

Includes Interest or Charges:
No

Has Priority Claim:
No

Priority Under:

Has Secured Claim:
No
Amount of 503(b)(9):
No
Based on Lease:
No
Subject to Right of Setoff:
No

Nature of Secured Amount:
Value of Property:
Annual Interest Rate:
Arrearage Amount:
Basis for Perfection:
Amount Unsecured:

Submitted By:
Steve Brenner on 07-Jul-2026 10:45:02 a.m. Pacific Time
Title:
Legal Counsel
Company:
Bachem Americas, Inc.

VN: 558E4F0EDDAA4E01A230C73CE7D2298F

Hi Oscar,
I have attached what I believe to be the quote to Red Queen for the services.
Are we able to generate a document that ties the purchase of the materials indicated below to Red Queen Therapeutics, Inc., along with a date indicating the materials were purchased for the services.
Query: If Red Queen was not in bankruptcy, what document would be created by Bachem to invoice Red Queen for the costs incurred?
An invoice from Bachem to Red Queen would be good supporting documentation.

Steve

From: Oscar Tippol <Oscar.Tippol@bachem.com>
Sent: Tuesday, June 30, 2026 2:42 PM
To: Divina Peralta <Divina.Peralta@bachem.com>; Steve Brenner <steve.brenner@bachem.com>; Loubna Kerkeb <Loubna.Kerkeb@bachem.com>; Marcos Urias <marcos.urias@bachem.com>; Henry Wilson II <william.wilson@bachem.com>; Carlos Mercado <carlos.mercado@bachem.com>
Subject: RE: Scrap List

Hello Divina:

Here is the quantity and value for material 4159768. This lot was purchased for RQ01 only.

Thank you.

Material	Material Description	Batch	Restricted-Use	BUn	Value Restricte
4159768	Chol-Ac-PEG8-OH	1000096838	469.500	G	53,072.38
			469.500	G	53,072.38


Material 4159768
Description Chol-Ac-PEG8-OH
Key date 06/30/2026

GMP item No
Criticallity T

Amount owed by Customer for costs incurred

Lv	Us	Plant	Ob...	Component number	Object description	Alt	Item	RC	Required qu
1	1	3110		4159301	RQ01 acetate salt	1	0370		6
1	1	3110		4159301	RQ01 acetate salt	2	0190		44

From: Divina Peralta <Divina.Peralta@bachem.com>
Sent: Tuesday, June 30, 2026 11:52 AM
To: Steve Brenner <steve.brenner@bachem.com>; Oscar Tippol <Oscar.Tippol@bachem.com>; Loubna Kerkeb <Loubna.Kerkeb@bachem.com>; Marcos Urias <marcos.urias@bachem.com>; Henry Wilson II <william.wilson@bachem.com>; Carlos Mercado <carlos.mercado@bachem.com>
Subject: RE: Scrap List



Material 4159768
Description Chol-Ac-PEG8-OH
Key date 07/01/2026

GMP item No
Criticallity T

Lv	U	Plant	Ob...	Component number	Object description	Alt	Item	R	Required qu
1	1	3110		4159301	RQ01 acetate salt	1	0370		6
1	1	3110		4159301	RQ01 acetate salt	2	0190		44

From: Steve Brenner <steve.brenner@bachem.com>
Sent: Wednesday, July 1, 2026 8:48 AM
To: Oscar Tippol <Oscar.Tippol@bachem.com>; Divina Peralta <Divina.Peralta@bachem.com>; Loubna Kerkeb <Loubna.Kerkeb@bachem.com>; Marcos Urias <marcos.urias@bachem.com>; Henry Wilson II <william.wilson@bachem.com>; Carlos Mercado <carlos.mercado@bachem.com>
Cc: Annalisa Valencia <annalisa.valencia@bachem.com>
Subject: RE: Scrap List

DocuSign Envelope ID: DEB803B0-610E-4919-ACEC-1CA658059B17

Quotation 73037

BACHEM

Bachem Americas, Inc
3132 Kashiwa Street
Torrance CA 90505 USA

Phone: +1 888 4222436
Fax: +310 5399428
www.bachem.com

Our reference: Keith Porter
Direct call: (310) 418-8685
E-mail: keith.porter@bachem.com

Red Queen Therapeutics
245 Main Street
Floor 12
Cambridge MA 02142
United States

Customer no: 229536
Your reference:

Delivery address:
Red Queen Therapeutics
245 Main Street
Floor 12
Cambridge MA 02142
United States

Quote Date: 10/06/2023

Valid until: 10/14/2023

To:
Mark Mitchnick, MD Director, CMC

Dear Mark,
It is my pleasure to provide you Bachem's quotation for RQ01 preclinical activities. Bachem will initiate a developmental feasibility batch to establish key process parameters for a successful and robust synthetic process, one suitable for larger-scale GMP production. A product specific UHPLC method (1.7micron media) will be optimized for use in fraction pooling and release of the IND enabling tox batch. The feasibility and tox batch will be placed on 1- and 3-month stability .

Terms:
- Bachem will make every best effort to deliver over 200g total RQ01.
- Purity requirements will be >90% utilizing full UHPLC methodology (Note - we see risk in making a direct comparison because the previous method utilized only a 3.5micron media and the total analysis time was only 35min. Based on experience with like molecules, Bachem's method would be 60 - 90min. Red Queen will provide a sample from current CDMO for comparison to Bachem's feasibility during UHPLC development)
- While it is expected to be 175 gm, Bachem and Red Queen will negotiate in good faith on the tox batch scale based on the results of the feasibility batch and UHPLC development
- Bachem wants the GMP project should the project move forward. Upon the successful completion of this project and progression of RQ-01development, Red Queen will award Bachem with the GMP business below. For clarity, ongoing GMP supply of RQ01 beyond the 500gm mentioned below will be subject to Bachem and Red Queen mutually agreeing to a separate supply agreement.
- Feasibility, UHPLC development, and feasibility stability are advances payment, total = $133,500. Forward looking payment terms are TBD for the tox batch onward (pending customer credit application)

→ never received.

Future GMP pricing:
- GMP batch, 500g - $1,200,000
- Establish primary reference standard from GMP batch - $15,000
- ICH 5-yr stability study - $82,000 (TBD in collaboration with Red Queen)

 The general sales terms and delivery conditions of the Bachem Group dated March 2022 are valid. These can be found on our website at www.bachem.com.

CONFIDENTIAL

Quotation 73037

BACHEM

Item	Material	Quantity	Price/Unit	Amount USD
10	4159301	25 G	3,100.00/G	77,500.00

Developmental synthesis of 4159301-RQ01 acetate salt

Scope:
The synthetic pathway, informed by RQ MEMO regarding Manufacture of RQ01 – 9 September, 2023, will be established relying on an Fmoc-Solid Phase Peptide Synthesis (SPPS) strategy and a medium-high loading Fmoc tricyclic amide linker Resin. The protocol will utilize Bachem's advanced toolbox of chemistry:
• Medium-high loading Fmoc tricyclic amide linker Resin
• Standard amino acid will be coupled with 2 equivalents using DIC/Oxyma procedure.
• After coupling of the Fmoc-R8-OH to the protected on-resin peptide chain, ring closing metathesis reaction (RCM) scouting will be performed using Grubbs catalyst *to staple R8 to S5. Then SPPS will proceed to afford the complete chain. Note* - imperative that RCM conditions are reproducible and the ratio of Cis/Trans isomers is reproducible.
• Orthogonal Lys(iVDde) on the C-term and conjugation to Chol-Ac-PEG8-OH at the conclusion of SPPS
• After completion of the SPPS, the resin will be dried to evaluate weight gain.
• Cleavage parameters will be optimized by screening varying cleavage conditions and scavenger additives..
• A purification process will be established using a standard stationary reversed phase (e.g. C18 or C8) and purification eluents.
• Use of ion exchange column for both purification/salt exchange (1D vs 2D), evaluation ammonium vs acetate
• The final product will be isolated using a standard lyophilization cycle.

Sequence:
Ac-Asp-Ile-Ser-Gly-Ile-Asn-Ala-Ser-Val-Val-Asn-Ile-Gln-R8-Glu-Ile-Asp-Arg-Leu-*Asn-S5-Val-Ala-Lys-Asn-Leu-Asn-Glu-Ser-Leu-Ile-Asp-Leu-Gln-Glu-Leu-Gly*-Lys(Chol_ Acetyl_PEG8_)-NH2 (Stapled on R8 and S5)
Counter ion : acetate (TBD) Deliverable:
• Aim of 25g RQ01, purity ≥90% (combined both isomers) with platform UHPLC method
• Analytical data sheet: appearance, purity and related substances (RP-UHPLC), ID (MS-ESI), content (CHN), and Elemental Impurities (ICP-MS)

Lead time:
10 weeks from start of production until QC release

20	4130009	1 PC	45,000.00/PC	45,000.00

Development of Analytical Test Methods for 4159301

Description:
Bachem will optimized a reversed phase UHPLC method capable of assessing the impurity profile of both test substances manufactured according to the Bachem production process (Q7A(1)) and ready the method for pre-validation. The method will be used to support GLP preclinical testing and should be suitable to determine impurities that might reasonably be expected based on knowledge of the chemical reactions and conditions involved (Q3A(2)). The objective of the development is a method that can be validated successfully considering the product specification for purity and related impurities. The requirements inferred from the EP monographs Ph. Eur. 2.2.29, 2.2.46, and 2034 "substances for pharmaceutical use" and the USP

 The general sales terms and delivery conditions of the Bachem Group dated March 2022 are valid. These can be found on our website at www.bachem.com.

CONFIDENTIAL

monograph <621> «Liquid Chromatography" should be considered. The final goal is a test procedure for the test related substances (UHPLC) according to the specification of the product that can be validated successfully in accordance with the recommendations of the ICH guideline Q2(3). Furthermore, the analytical method should be stability indicating, and ideally LC-MS compatible.

References:
(1)ICH Harmonised Tripartite Guideline (Q7) 'Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients' (Nov. 2000)
(2)ICH Harmonised Tripartite Guideline (Q3A(R2)) 'Impurities in New Drug Substances' (Oct. 2006)
(3)ICH Harmonised Tripartite Guideline (Q2(R1)) 'Validation of Analytical Procedures: Text and Methodology' (Nov. 2005)

Scope of service:
1. Evaluation of different stationary and mobile phases (reversed phase separation)
2. Optimization of the chromatographic conditions such as column temperature, flow rate, gradient
3. Assessment of potential related impurity/substances below the product UV peak (peak purity) by LC-MS
4. Stability indicating nature will be evaluated using thermally stressed peptide samples (16 hours at 80°C for solid and 1 hour at 100°C for liquid).
5. Testing the suitability of the final method for validation and routine analysis aspects (*Pre-validation*)
6. Comparison of Red Queen sample using developed method

Deliverable: Method development report

Prerequisite Material Requirements:
400 mg from feasibility batch

Lead time: 8 weeks

30	4130001	1 PC	11,000.00/PC	11,000.00

Developmental Stability Study of 4159301-RQ01

Purpose:
Provide preliminary evidence on how the quality of the active substance varies with the time under the influence of a variety of environmental factors such as temperature and humidity. Establish a preliminary retest period and storage condition for the active substance.

Scope:
1. Scope and regulatory basis of the study
The purpose of the developmental stability study is to provide preliminary evidence on how the quality of the active substance varies with time under the influence of a variety of environmental factors such as temperature and humidity, and to establish a preliminary retest period and storage condition for the active substance. The developmental stability study is based on the ICH Harmonised Tripartite Guideline (Q1A(R2)) 'Stability Testing of New Drug Substances and Products' (Current version).

2. Stability containers and stability samples
The study will be conducted on the active substance packed in glass containers. The study is performed on one single batch of the active substance. Single portions are stored for each assay at the planned time point/temperature. Each container

 The general sales terms and delivery conditions of the Bachem Group dated March 2022 are valid. These can be found on our website at www.bachem.com.

CONFIDENTIAL

contains approximately 30 mg of the active substance.

3. Storage conditions and time points
A portion will be removed at each time point and storage condition given in the sampling plan below. Release data will be used for time point 0 of the developmental stability study (if applicable).

-Storage condition of -20°C ±5 °C:
Appearance and purity at 1- and 3-month time points. Material for 5 additional pulls will be stored at study initiation to be tested, at additional cost to RQ, if the program is extended.

-Storage condition of +25°C ± 5 °C/60% ± 5% RH:
Appearance and purity at 1- and 3-month time points. Material for 5 additional pulls will be stored at study initiation to be tested, at additional cost to RQ, if the program is extended.

5. Documentation
The final stability report will be prepared upon completion of the 3-months analyses.

Deliverables:
Final Stability Report

Material:
Material needed (0.6 g) RQ-01 (Lot tbd) from development batch in Bachem inventory

Payment Terms:
The pricing provided above includes sample collection, storage and maintenance, analysis of material according to the testing protocol described above and periodic reporting of results. The cost of peptide is included in price.

40	4159301	175 G	1,050.00/G	183,750.00

RQ01 acetate salt

Scope:
It is targeted to manufacture a first developmental scale-up nonGMP batch for IND enabling tox studies, based on the basic manufacturing process established during feasibility.

- Linear scale-up of process parameters established in feasibility. (RCM) scouting will be performed in sub-lots using Grubbs catalyst at this larger scale to staple R8 to S5. Note - imperative that RCM conditions are reproducible and the ratio of Cis/Trans isomers is reproducible moving into GMP production.
- Incorporation of recommendations from the feasibility.
- Implementation of in process controls (IPCs)

Purity:
>90% (product specific RP-UHPLC). While Bachem recommends a lower purity (~90%) for preclinical material is suggested allowing for broad impurity coverage during tox studies, the target will be discussed between RQ and Bachem as the program progresses. Higher purity material (lower impurity levels), while attainable at this stage, may not afford comprehensive impurity qualification. A more comprehensive qualification of impurities at this stage affords Bachem/Red Queen more flexibility to "tweak" the process for desired efficiencies as the program advances. New impurities arising in future GMP batches not present in a toxicology batch may require additional tox studies, leading to trial delays.
Sequence:

 The general sales terms and delivery conditions of the Bachem Group dated March 2022 are valid. These can be found on our website at www.bachem.com.

Ac-Asp-Ile-Ser-Gly-Ile-Asn-Ala-Ser-Val-Val-Asn-Ile-Gln-R8-Glu-Ile-Asp-Arg-Leu-Asn-S5-Val-Ala-Lys-Asn-Leu-Asn-Glu-Ser-Leu-Ile-Asp-Leu-Gln-Glu-Leu-Gly-Lys(Chol_ Acetyl_PEG8_)-NH2 (Stapled on R8 and S5)

Counter ion
TBD

Deliverable:
• Aim of 175g RQ01, purity ≥90% (combined both isomers) with developed UHPLC method
• Analytical data sheet: appearance, purity and related substances (RP-UHPLC), ID (MS-ESI), counterion (HPLC/IC), AAA, water (KF), content (CHN), Elemental Impurities (ICP-MS), Bioburden and Endotoxin

Lead time:
14 weeks from start of production until QC release.

50	4130001	1 PC	11,000.00/PC	11,000.00

Developmental Stability Study of 4159301-RQ01

Purpose:
Provide preliminary evidence on how the quality of the active substance varies with the time under the influence of a variety of environmental factors such as temperature and humidity. Establish a preliminary retest period and storage condition for the active substance.

Scope:
1. Scope and regulatory basis of the study
The purpose of the developmental stability study is to provide preliminary evidence on how the quality of the active substance varies with time under the influence of a variety of environmental factors such as temperature and humidity, and to establish a preliminary retest period and storage condition for the active substance. The developmental stability study is based on the ICH Harmonised Tripartite Guideline (Q1A(R2)) 'Stability Testing of New Drug Substances and Products' (Current version).

2. Stability containers and stability samples
The study will be conducted on the active substance packed in glass containers. The study is performed on one single batch of the active substance. Single portions are stored for each assay at the planned time point/temperature. Each container contains approximately 30 mg of the active substance.

3. Storage conditions and time points
A portion will be removed at each time point and storage condition given in the sampling plan below. Release data will be used for time point 0 of the developmental stability study (if applicable).

-Storage condition of -20°C ±5 °C:
Appearance and purity at 1- and 3-month time points

-Storage condition of +25°C ± 5 °C/60% ± 5% RH:
Appearance and purity at 1- and 3-month time points

5. Documentation
The final stability report will be prepared upon completion of the 3-months analyses.

Deliverables:

 The general sales terms and delivery conditions of the Bachem Group dated March 2022 are valid. These can be found on our website at www.bachem.com.

CONFIDENTIAL

Quotation 73037

BACHEM

Final Stability Report Material: Material needed (0.3 g) RQ-01 (Lot tbd) from tox batch in Bachem inventory Payment Terms: The pricing provided above includes sample collection, storage and maintenance, analysis of material according to the testing protocol described above and periodic reporting of results. The cost of peptide is included in price.		
Subtotal		328,250.00
	Dry-Ice Shipment	3,100.00
Total amount USD		***331,350.00***

Payment terms: Advance Payment
Incoterms 2020: FCA Bachem Americas, Torrance CA
Delivery method: FedEx

FCA delivery for two shipments. Bachem will arrange the shipments for Red Queen, including packaging + dry ice + data logger. Shipments outside the U.S. can be made to entry port only, client is responsible for Duty, VAT, taxes, clearance, and additional shipping cost to final destination.

Please contact me at 310-418-8685 if I can provide additional information. When placing your order, please reference the quotation number on your purchase order and send back to me by email at keith.porter@bachem.com. For a complete list of terms and conditions associated with this quotation, please consult the Bachem website.

Keith Porter
Business Development Manager
Bachem Americas

Approved by:

Bachem Americas, Inc.

DocuSigned by:
By: Christopher J McGee
F1B565F8957F477...

Name: Christopher J McGee

Title: VP & Head, Global Business Development

Date: Oct 9, 2023

Red Queen Therapeutics.

By:

Name:

Title: CEO

Date: 10/10/23

 The general sales terms and delivery conditions of the Bachem Group dated March 2022 are valid. These can be found on our website at www.bachem.com.

CONFIDENTIAL